Brown Tumour of Hyperparathyroidism

A brown tumour is a focal, tumour-like, lytic bone lesion: the localised end-stage of osteitis fibrosa cystica, the skeletal manifestation of hyperparathyroidism. The word "tumour" is a misnomer, driven by its lytic, mass-like appearance.

What fills the cavity. Sustained excess parathyroid hormone (PTH) drives osteoclastic bone resorption, and the resulting cavities fill with vascular fibrous tissue, osteoclast-type giant cells, reactive woven bone, microhaemorrhage and haemosiderin. The brown colour seen at operation comes from the haemosiderin and the rich vascularity, not from any pigment-producing cell.

Reactive, with a caveat. It is classically regarded as a reactive process rather than a true neoplasm, and it has no metastatic potential. The molecular findings under Pathology mean "purely reactive" can no longer be stated as settled fact.

Why it matters. It is the classic giant cell tumour mimic: histologically indistinguishable from giant cell tumour of bone, so the diagnosis depends on the biochemical context, and mislabelling it leads to the wrong operation. It can be the first presentation of otherwise occult hyperparathyroidism, including parathyroid carcinoma. It usually regresses after the parathyroid disease is treated, so the management priority is the gland, not the bone.

The causes. Any of the three types of hyperparathyroidism can produce it:

• Secondary hyperparathyroidism from chronic kidney disease is now the most common driver worldwide, reflecting the global dialysis population
• Primary hyperparathyroidism, usually a single parathyroid adenoma, is the classic textbook cause; brown tumours are now an uncommon presentation of it because primary HPT is detected earlier on routine calcium testing
• Tertiary hyperparathyroidism, from autonomous glands after long-standing secondary HPT, is a less common but recognised cause

Who and where. Brown tumours are more frequent with more severe and longer-standing hyperparathyroidism. Common sites include the pelvis, ribs, jaws (mandible and maxilla), femur and other long bones, and lesions may be solitary or multiple.

View larger

The PTH-osteoclast axis. Parathyroid hormone is the master regulator of calcium. In excess it acts on bone, kidney and vitamin D:

1. Increases osteoclastic bone resorption, indirectly via the RANKL pathway on osteoblastic stromal cells, liberating calcium and phosphate from bone
2. Increases renal calcium reabsorption and phosphate excretion
3. Stimulates renal 1-alpha-hydroxylase, raising active vitamin D and gut calcium absorption

From resorption to lesion. When PTH is persistently high, resorption outpaces formation. Generalised demineralisation produces osteitis fibrosa cystica; focal exuberant resorption with reactive repair produces the discrete brown tumour. The biochemistry both explains the disease and tells you the type, as set out under Classification.

Histology. The lesion is rich in giant cells, and the characteristic findings are these:

• Numerous osteoclast-type multinucleated giant cells
• A vascular, fibrous (spindle-cell) stroma
• Haemosiderin deposition and areas of old and recent haemorrhage
• Reactive woven bone and a background of generalised osteoclastic resorption

View larger

Why the slide cannot decide. These features are indistinguishable from giant cell tumour of bone and overlap with giant cell reparative granuloma and the giant cell-rich variants of other lesions. The pathologist cannot reliably separate them on morphology alone, so the diagnosis is confirmed by the biochemistry (raised PTH, abnormal calcium) and the clinical context.

View larger

The molecular caveat. Although classically considered purely reactive, the giant cell-rich lesions of the jaws in hyperparathyroidism can harbour activating KRAS mutations with downstream MAPK/ERK pathway activation. That places them in the same RAS-driven spectrum as some histological mimics and explains the close morphological overlap with other giant cell lesions. It does not change the clinical message: treat the parathyroid disease.

What regression means. Brown tumours regress and remineralise once PTH is normalised, but that promise is only useful with a timeline attached and a plan for the lesion that fails to settle. Both are what an examiner asks next.

The expected course. Bone turnover falls quickly once PTH normalises. Radiologically the lytic lesion fills in and remineralises gradually over months, sometimes taking a year or more for a large lesion to sclerose fully. A residual sclerotic or cystic focus can persist on imaging even after clinical and biochemical cure, and a healed, remineralised lesion is not the same as a failed treatment.

View larger

Monitoring. Serial biochemistry (calcium, phosphate, PTH and alkaline phosphatase) is the primary measure of success: falling PTH and normalising calcium confirm the gland is controlled. Serial imaging documents remineralisation and is reassuring when it tracks the biochemistry.

View larger

View larger

When a lesion does not regress. Persistence, progression or recurrence after apparent treatment usually means the parathyroid disease is incompletely controlled, not aggressive local behaviour or a lesion behaving like a neoplasm. The causes to look for:

• A missed or ectopic adenoma
• A supernumerary or residual gland after surgery
• Under-treated secondary hyperparathyroidism in a dialysis patient

The response. Re-check the biochemistry and re-image the parathyroids (repeat ultrasound and sestamibi, with 4D-CT if needed), rather than escalate to aggressive bone resection. Only a genuinely persistent, symptomatic lesion despite documented biochemical cure justifies bone-directed surgery: curettage and grafting, or fixation for mechanical failure.

Why examiners like it. It is the archetypal "do not be fooled" giant cell lesion, testing whether you check biochemistry before operating. It links endocrinology, nephrology, radiology and orthopaedic oncology in one topic, which suits a viva that crosses subspecialties, and it rewards the candidate who states the principle clearly: treat the parathyroid disease first, operate on the bone only for mechanical or neurological reasons.

The one-line answer. "A brown tumour is a reactive giant cell lesion of hyperparathyroidism that is histologically identical to giant cell tumour of bone, so I would check the calcium and PTH, confirm and classify the hyperparathyroidism, and treat the parathyroid gland first - the lesion usually regresses, and I reserve bone surgery for fracture or neural compression."

The most useful classification is by the underlying hyperparathyroidism, because it dictates treatment of the gland. Site and number, and the clinical problem that brings the orthopaedic surgeon in, add the rest.

The skeleton. Patients describe bone pain, often diffuse, or have a lytic lesion that is palpable or found on imaging. Pathological fracture through weakened bone is a common orthopaedic presentation, and severe, long-standing disease brings skeletal deformity.

View larger

View larger

The hyperparathyroidism. The systemic features follow the old rhyme below. Severe disease adds proximal muscle weakness and hyperreflexia.

How it reaches the orthopaedic surgeon. Three presenting scenarios are worth recognising:

• A jaw swelling referred from a dentist or maxillofacial team that turns out to be the first sign of hyperparathyroidism
• A dialysis patient with bone pain and a lytic lesion (secondary HPT)
• An apparent giant cell tumour that does not fit: multiple lesions, abnormal calcium, or renal failure

View larger

Examination. Look for local tenderness or a firm swelling over the lesion and for signs of the underlying disease, such as features of chronic kidney disease. Assess the neurology if a spinal lesion is suspected.

Red flags. Each of these should prompt a PTH check:

• A giant cell lesion in an unusual location for GCT (e.g. rib, jaw, multiple bones)
• Multiple lytic lesions
• A patient with renal failure or known hypercalcaemia
• Any giant cell lesion before a definitive operation is planned

Biochemistry is the key to the diagnosis. It is the single most important investigation: a giant cell lesion of bone must have calcium and PTH checked before treatment, and operating on an undiagnosed brown tumour is a classic error.

The giant cell differential. The lesions that share its appearance, and what separates them:

X-rayCT / MRINuclear / localisation

The lesion. A well-defined, expansile lytic lesion, often with a thinned cortex. It may be solitary or multiple, and a pathological fracture may be present.

The background signs of hyperparathyroidism. These are the high-yield findings on the rest of the film:

• Subperiosteal resorption on the radial side of the middle phalanges - the classic hallmark
• Acro-osteolysis (terminal tuft resorption)
• Salt-and-pepper skull - granular mixed lucency and sclerosis
• Generalised demineralisation and insufficiency fractures
• Rugger-jersey spine (alternating sclerotic bands) in renal osteodystrophy

Putting it together. The brown tumour on its own is non-specific. It is the combination with these background signs and the biochemistry that points to the diagnosis.

View larger

View larger

View larger

CT defines the lesion, cortical integrity and fracture risk. It is useful for axial lesions (pelvis, spine) and for surgical planning.

MRI often shows a heterogeneous lesion of low-to-intermediate signal, with areas reflecting haemosiderin and haemorrhage. It assesses soft-tissue extent and, in spinal lesions, neural compression, but it cannot reliably distinguish brown tumour from other giant cell-rich lesions; again, biochemistry is decisive.

View larger

Bone scan. It may show multiple foci of increased uptake (high turnover), which can mimic metastatic disease - a known trap.

Parathyroid localisation. Once hyperparathyroidism is confirmed, localisation is required to plan gland surgery: neck ultrasound and sestamibi (Tc-99m MIBI) scintigraphy, with 4D-CT in difficult cases. The imaging is aimed at the parathyroid gland, because that is what is being treated.

View larger

Biopsy, with caution. Biopsy shows giant cell-rich tissue but cannot distinguish brown tumour from giant cell tumour, and if hyperparathyroidism has not been considered it may even mislead towards an aggressive tumour diagnosis. Check calcium and PTH first. Biopsy is reserved for cases where the diagnosis remains uncertain after biochemistry, ideally in a specialist bone-tumour centre.

Treat the gland first. The cornerstone of management is correcting the hyperparathyroidism. Once PTH normalises, bone turnover falls and the great majority of brown tumours regress and remineralise, often without any direct bone surgery. Bone surgery is a second-line, anatomy-driven decision.

The sequence. The pathway runs in five steps:

1. Confirm: for any giant cell lesion of bone, check serum calcium, phosphate, PTH, ALP and renal function
2. Classify the hyperparathyroidism as primary, secondary or tertiary, because the type dictates how the gland is treated
3. Treat the parathyroid disease
4. Address the bone only if needed
5. Monitor regression with biochemistry and serial imaging after PTH control, expecting remineralisation over months

Primary / Tertiary HPTSecondary HPT (CKD)When To Operate On The Bone

Surgical cure of the gland. Parathyroidectomy is the definitive treatment, either a focused adenomectomy or exploration of all four glands depending on localisation; pre-operative ultrasound and sestamibi guide a focused approach. After successful surgery calcium and PTH fall, so watch for transient hypocalcaemia. The brown tumours typically remineralise over the following months.

Hungry Bone Syndrome

After parathyroidectomy in patients with a large skeletal burden, anticipate hungry bone syndrome: rapid skeletal uptake of calcium, with profound, prolonged hypocalcaemia requiring aggressive calcium and vitamin D replacement.

Medical control first. Optimise dialysis and phosphate binders to control hyperphosphataemia, and lower PTH with active vitamin D analogues and calcimimetics (e.g. cinacalcet). Do not rush to bone surgery; optimise the metabolic disease first.

When to remove the glands. Parathyroidectomy is reserved for medically refractory secondary HPT with severe symptoms, very high PTH, or progressive brown tumours. Renal transplantation may resolve the underlying drive.

Bone-directed surgery is second-line. It is indicated for an anatomical or mechanical problem rather than for the lesion itself:

• Impending or actual pathological fracture - stabilisation (internal fixation), sometimes with curettage and grafting
• Spinal lesion with neural compression - decompression and stabilisation as a surgical urgency
• Persistent symptomatic lesion that fails to regress despite normalised PTH

The wrong operation. Treating a brown tumour as a giant cell tumour, with denosumab, aggressive curettage or resection, is the wrong operation. Avoid aggressive resection as a first step: the lesion is reactive and usually settles when the gland is treated.

View larger

From the lesion. Pathological fracture through weakened bone, neural compression from spinal or skull-base lesions, and deformity and functional impairment in severe, long-standing disease.

From the hyperparathyroidism. Renal stones, nephrocalcinosis and progressive renal impairment; cardiovascular and soft-tissue calcification, especially in CKD; and severe hypercalcaemia with its systemic effects.

From treatment. Hungry bone syndrome after parathyroidectomy, and the standard surgical risks if bone-directed surgery is undertaken.

Prognosis. With successful control of the hyperparathyroidism most brown tumours regress and remineralise, and the prognosis is excellent. The overall outlook is determined largely by the underlying cause, such as the renal disease in secondary HPT or the rare parathyroid carcinoma in primary HPT.

An uncommon but high-stakes site. Axial lesions with neural compression are a surgical urgency, and a spinal brown tumour is the scenario most likely to force early bone surgery and the one most often mislabelled. Vertebral brown tumours are rare, but when present an expansile lytic lesion of a vertebral body, pedicle or lamina can encroach on the cord or nerve roots.

Why it is missed. The presentation overlaps exactly with an aggressive tumour: a young or middle-aged adult with an expansile destructive vertebral lesion. It is therefore repeatedly misdiagnosed as giant cell tumour, aneurysmal bone cyst or metastasis and biopsied or resected before anyone checks the biochemistry.

Presentation. Localised spinal pain, often with radicular pain (radiculopathy) from root involvement. Myelopathy or cauda equina features (weakness, sensory level, sphincter disturbance) appear when the canal is compromised, and these mandate urgent imaging and a decision about decompression.

Two problems, two answers. The neurological emergency is treated on its own merits: urgent MRI, then decompression and stabilisation where there is progressive deficit or instability, exactly as for any compressive vertebral lesion. The metabolic driver is still corrected in parallel, because even after decompression, normalising the parathyroid disease is what allows the residual lesion to remineralise and prevents recurrence. So if there is a neurological deficit, decompress and stabilise the spine now, but check calcium and PTH before and after so that the true diagnosis is not missed and the gland is treated to consolidate the result.

The cautionary case. In the reported cervical case, a young man had a C6 lesion treated initially as an osteoclastoma (giant cell tumour). Only persistently high calcium and PTH revealed primary hyperparathyroidism, and the bone recovered after parathyroidectomy once the underlying disease was addressed.

View larger

Global Epidemiology

• Brown tumours are uncommon and becoming rarer in primary hyperparathyroidism in high-income settings, because routine calcium testing detects the disease before severe bone involvement develops.
• Secondary hyperparathyroidism from chronic kidney disease is now the leading driver globally, tracking the worldwide growth of the dialysis population.
• Common sites across populations include the pelvis, ribs, jaws and long bones; lesions may be solitary or multiple.

Side-by-Side Guidance and Consensus

Where guidance genuinely differs, the divergence is in the threshold for parathyroidectomy in secondary HPT (earlier surgery in some centres versus prolonged medical therapy with calcimimetics in others), not in the principle that the parathyroid disease drives the lesion.

Registry and Trial Evidence

• No implant joint-registry (NJR/AJRR/AOANJRR) tracks brown tumour, because management is metabolic and reconstruction (when needed) is fixation or grafting rather than arthroplasty.
• Evidence is built from case series and multicentre retrospective cohorts (e.g. CKD-MBD oral/maxillofacial series) and from the parathyroid disease trials underpinning calcimimetic and surgical practice.

High- vs Limited-Resource Practice